Renal cell cancer

Area of Science:

• Oncology
• Medical Science

Background:

• Metastatic renal cell cancer (mRCC) treatment historically relied on interferon and interleukin-2.
• Advances in understanding renal cancer biology have led to novel targeted therapies.
• Key pathways targeted include vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR).

Purpose of the Study:

• To review the efficacy of novel targeted agents in metastatic renal cell cancer.
• To discuss the integration of new therapies into mRCC management.
• To highlight the promising future of renal cancer treatment.

Main Methods:

• Review of randomized clinical trials and early studies on targeted agents for mRCC.
• Analysis of agents targeting VEGF and mTOR pathways.
• Discussion of clinical trial data for sunitinib malate, sorafenib tosylate, temsirolimus, and bevacizumab/interferon alfa.

Main Results:

• Sunitinib malate, sorafenib tosylate, temsirolimus, and bevacizumab/interferon alfa have demonstrated improved clinical outcomes in randomized trials.
• Other antiangiogenic agents have shown activity in preliminary studies.
• These novel therapies represent a significant advancement over traditional treatments.

Conclusions:

• Novel targeted therapies have significantly altered the natural history of metastatic renal cell cancer.
• Ongoing and planned clinical trials are crucial for defining optimal treatment strategies.
• The efficacy of these agents offers a promising outlook for future renal cancer therapy.